A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 196,200 shares of ITCI stock, worth $16.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
196,200
Previous 222,400 11.78%
Holding current value
$16.7 Million
Previous $15.2 Million 5.82%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$67.99 - $80.84 $1.78 Million - $2.12 Million
-26,200 Reduced 11.78%
196,200 $14.3 Million
Q2 2024

Aug 09, 2024

BUY
$64.76 - $79.84 $8.14 Million - $10 Million
125,700 Added 129.99%
222,400 $15.2 Million
Q1 2024

May 13, 2024

SELL
$64.37 - $75.65 $3.59 Million - $4.21 Million
-55,700 Reduced 36.55%
96,700 $6.69 Million
Q4 2023

Feb 13, 2024

SELL
$46.37 - $73.65 $5.17 Million - $8.22 Million
-111,600 Reduced 42.27%
152,400 $10.9 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $1.22 Million - $1.51 Million
23,500 Added 9.77%
264,000 $13.8 Million
Q2 2023

Aug 11, 2023

BUY
$54.67 - $66.44 $13.1 Million - $16 Million
240,500 New
240,500 $15.2 Million
Q2 2020

Aug 13, 2020

SELL
$14.35 - $26.64 $2.17 Million - $4.03 Million
-151,400 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$12.31 - $33.12 $1.86 Million - $5.01 Million
151,400 New
151,400 $2.33 Million
Q3 2019

Nov 13, 2019

SELL
$7.47 - $14.03 $614,781 - $1.15 Million
-82,300 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$10.65 - $14.29 $17,040 - $22,864
-1,600 Reduced 1.91%
82,300 $1.07 Million
Q1 2019

May 14, 2019

SELL
$10.9 - $14.09 $609,310 - $787,631
-55,900 Reduced 39.99%
83,900 $1.02 Million
Q4 2018

Feb 13, 2019

BUY
$10.36 - $20.96 $1.45 Million - $2.93 Million
139,800 New
139,800 $1.59 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.05B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.